Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5764856 | 0.98 | KCNH2 (0.42) | KCNH2HTR2ATDP1MEN1KMT2A | |
| SCHEMBL7447631 | 0.98 | KCNH2 (0.42) | KCNH2HTR2ATDP1MEN1KMT2A | |
| SCHEMBL2141121 | 0.94 | HDAC3 (0.35) | KCNH2HDAC3HDAC1HDAC2MEN1 | |
| SCHEMBL4680152 | 0.86 | TAAR1 (0.31) | HDAC3HDAC1HDAC2 | |
| SCHEMBL406610 | 0.79 | LIPG (0.46) | KCNH2TDP1MEN1KMT2ALIPG | |
| SCHEMBL815744 | 0.79 | KCNH2 (0.40) | KCNH2HTR2ATDP1L3MBTL1LIPG | |
| SCHEMBL7015955 | 0.79 | TAAR1 (0.44) | HTR2A | |
| SCHEMBL8664333 | 0.79 | KCNH2 (0.37) | KCNH2HTR2ATDP1L3MBTL1LIPG | |
| SCHEMBL19405386 | 0.79 | — | — | |
| SCHEMBL455820 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003000750-A1 | POLYMERIZATION PROCESSES USING A HIGHLY ACTIVE CATALYST | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2003-01-03 | — | — | WO | claimed |
| CN-118165031-A | Nitrile compound, electrolyte, secondary battery and device | 蔚来电池科技(安徽)有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-116589494-A | Magnesium/calcium borate, and preparation method and application thereof | 浙江大学杭州国际科创中心 | 2023-08-15 | — | — | CN | disclosed |
| CN-107004906-B | Magnesium-containing electrolyte | 富士胶片和光纯药株式会社 | 2020-04-21 | — | — | CN | disclosed |
| US-10367231-B2 | Magnesium-containing electrolytic solution | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2019-07-30 | — | — | US | disclosed |
| EP-3226340-B1 | MAGNESIUM-CONTAINING ELECTROLYTIC SOLUTION | FUJIFILM WAKO PURE CHEMICAL CORP (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-20170331154-A1 | MAGNESIUM-CONTAINING ELECTROLYTIC SOLUTION | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2017-11-16 | — | — | US | disclosed |
| EP-3226340-A1 | MAGNESIUM-CONTAINING ELECTROLYTIC SOLUTION | Wako Pure Chemical Industries, Ltd. (JP) | 2017-10-04 | — | — | EP | disclosed |
| EP-2614050-B1 | 1,5-DIARYL-2-ALKYLPYRROLE-3-SUBSTITUTED NITRO ESTERS, SELECTIVE COX-2 INHIBITORS AND NITRIC OXIDE DONORS | Rottapharm Biotech Srl (IT) | 2016-01-20 | — | — | EP | disclosed |
| US-9162979-B2 | 1,5-Diary1-2-alkylpyrrole-3-substituted nitro esters, selective COX-2 inhibitors and nitric oxide donors | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-10-20 | — | — | US | disclosed |
| EP-2614050-A1 | 1,5-DIARYL-2-ALKYLPYRROLE-3-SUBSTITUTED NITRO ESTERS, SELECTIVE COX-2 INHIBITORS AND NITRIC OXIDE DONORS | Rottapharm S.p.A. (IT) | 2013-07-17 | — | — | EP | disclosed |
| US-20130165494-A1 | 1,5-Diaryl-2-alkylpyrrole-3-Substituted Nitro Esters, Selective COX-2 Inhibitors and Nitric Oxide Donors | ROTTAPHARM S.P.A. (IT) | 2013-06-27 | — | — | US | disclosed |
| WO-2012032479-A1 | L,5-DIARYL-2-ALKVLPVRROLE-3-SUBSTITUTED NITRO ESTERS, SELECTIVE COX-2 INHIBITORS AND NITRIC OXIDE DONORS | ROTTAPHARM S.P.A. (IT) | 2012-03-15 | — | — | WO | disclosed |
| WO-2003000750-A1 | POLYMERIZATION PROCESSES USING A HIGHLY ACTIVE CATALYST | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2003-01-03 | — | — | WO | disclosed |
| CN-1383823-A | Methods of treating or inhibiting neutrophil chemotaxis by administering MEK inhibitors | WARNER LAMBERT CO (US) | 2002-12-11 | — | — | CN | disclosed |
| EP-1165557-A1 | ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS | NEUROGEN CORPORATION (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059905-A1 | ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS | NEUROGEN CORPORATION (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10367231-B2 | Magnesium-containing electrolytic solution | CA1, CA3, CA2 | KCNH2 67/4885HTR2A 4323/4885HDAC3 4126/4885 |
| US-20130165494-A1 | 1,5-Diaryl-2-alkylpyrrole-3-Substituted Nitro Esters, Selective COX-2 Inhibitors and Nitric Oxide Donors | NOS3, PTGER3, PTGES3 | KCNH2 839/4885HTR2A 301/4885HDAC3 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.